Clinical trial
Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After…
NCT01243398 · University of Oxford, Other · Completed
Key facts
| NCT number | NCT01243398 |
|---|---|
| Title | Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy |
| Official title | Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gefitinib (Iressa®) Versus Placebo in Esophageal Cancer Progressing After Chemotherapy |
| Lead sponsor | University of Oxford, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer |
| Intervention type | Procedure |
| Interventions | quality-of-life assessment |
| Enrollment | 450 |
| Start date | Mar 1, 2009 |
| Primary completion | May 1, 2012 |
| Completion | May 1, 2012 |
| First posted | Nov 18, 2010 |
| Last update posted | Nov 29, 2012 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: